{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:39:40Z","timestamp":1765546780517,"version":"3.37.3"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In the CYD14 (NCT01373281) and CYD15 (NCT01374516) dengue vaccine efficacy trials, month 13 neutralizing antibody (nAb) titers correlated inversely with risk of symptomatic, virologically confirmed dengue (VCD) between month 13 (1 month after final dose) and month 25. We assessed nAb titer as a correlate of instantaneous risk of hospitalized VCD (HVCD), for which participants were continually surveilled for 72 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using longitudinal nAb titers from the per-protocol immunogenicity subsets, we estimated hazard ratios (HRs) of HVCD by current nAb titer value for 3 correlate\/endpoint pairs: average titer across all 4 serotypes\/HVCD of any serotype (HVCD-Any), serotype-specific titer\/homologous HVCD, and serotype-specific titer\/heterologous HVCD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline-seropositive placebo recipients with higher average titer had lower instantaneous risk of HVCD-Any in 2- to 16-year-olds and in 9- to 16-year-olds (HR, 0.26 or 0.15 per 10-fold increase in average titer by 2 methods [95% confidence interval {CI}, .14\u2013.45 and .07\u2013.34, respectively]) pooled across both trials. Results were similar for homologous HVCD. There was evidence suggesting increased HVCD-Any risk in participants with low average titer (1:10 to 1:100) compared to seronegative participants (HR, 1.85 [95% CI, .93\u20133.68]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Natural infection\u2013induced nAbs were inversely associated with hospitalized dengue, upon exceeding a relatively low threshold.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiab342","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T19:12:14Z","timestamp":1624561934000},"page":"332-340","source":"Crossref","is-referenced-by-count":4,"title":["Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials"],"prefix":"10.1093","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9655-7502","authenticated-orcid":false,"given":"Ying","family":"Huang","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"},{"name":"Department of Biostatistics, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D","family":"Williamson","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Moodie","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay N","family":"Carpp","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Chambonneau","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Marcy-L\u2019Etoile, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A","family":"DiazGranados","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"},{"name":"Department of Biostatistics, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"year":"2020","author":"World Health Organization.","key":"2022031117303484000_CIT0001"},{"key":"2022031117303484000_CIT0002","doi-asserted-by":"crossref","first-page":"e1760","DOI":"10.1371\/journal.pntd.0001760","article-title":"Refining the global spatial limits of dengue virus transmission by evidence-based consensus","volume":"6","author":"Brady","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2022031117303484000_CIT0003","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"2022031117303484000_CIT0004","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(14)60572-9","article-title":"Dengue","volume":"385","author":"Guzman","year":"2015","journal-title":"Lancet"},{"key":"2022031117303484000_CIT0005","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.pt.2018.07.007","article-title":"The estimates of the health and economic burden of dengue in Vietnam","volume":"34","author":"Hung","year":"2018","journal-title":"Trends Parasitol"},{"key":"2022031117303484000_CIT0006","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4269\/ajtmh.2011.10-0503","article-title":"Economic impact of dengue illness in the Americas","volume":"84","author":"Shepard","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2022031117303484000_CIT0007","doi-asserted-by":"crossref","first-page":"e2055","DOI":"10.1371\/journal.pntd.0002055","article-title":"Economic and disease burden of dengue in Southeast Asia","volume":"7","author":"Shepard","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2022031117303484000_CIT0008","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3201\/eid2604.190729","article-title":"Health-related quality of life after dengue fever, Morelos, Mexico, 2016-2017","volume":"26","author":"Schulte","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2022031117303484000_CIT0009","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2015.09.108","article-title":"Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward","volume":"33","author":"Guy","year":"2015","journal-title":"Vaccine"},{"key":"2022031117303484000_CIT0010","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"2022031117303484000_CIT0011","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031117303484000_CIT0012","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"2022031117303484000_CIT0013","first-page":"329","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, April 2018\u2014conclusions and recommendations","volume":"23","author":"World Health Organization.","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"2022031117303484000_CIT0014","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"J Infect Dis"},{"key":"2022031117303484000_CIT0015","doi-asserted-by":"crossref","first-page":"e0234236","DOI":"10.1371\/journal.pone.0234236","article-title":"Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America","volume":"15","author":"Carpp","year":"2020","journal-title":"PLoS One"},{"key":"2022031117303484000_CIT0016","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2022031117303484000_CIT0017","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/biomet\/87.1.37","article-title":"On fitting Cox\u2019s proportional hazards models to survey data","volume":"87","author":"Lin","year":"2000","journal-title":"Biometrika"},{"key":"2022031117303484000_CIT0018","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10985-016-9364-1","article-title":"Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling","volume":"23","author":"Fu","year":"2017","journal-title":"Lifetime Data Anal"},{"key":"2022031117303484000_CIT0019","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/oxfordjournals.aje.a113932","article-title":"Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak","volume":"120","author":"Sangkawibha","year":"1984","journal-title":"Am J Epidemiol"},{"key":"2022031117303484000_CIT0020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4269\/ajtmh.1988.38.172","article-title":"A prospective study of dengue infections in Bangkok","volume":"38","author":"Burke","year":"1988","journal-title":"Am J Trop Med Hyg"},{"key":"2022031117303484000_CIT0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4269\/ajtmh.1990.42.179","article-title":"Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study","volume":"42","author":"Guzman","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"2022031117303484000_CIT0022","first-page":"311","article-title":"Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered","volume":"42","author":"Halstead","year":"1970","journal-title":"Yale J Biol Med"},{"key":"2022031117303484000_CIT0023","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"2022031117303484000_CIT0024","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41586-018-0157-4","article-title":"Reconstruction of antibody dynamics and infection histories to evaluate dengue risk","volume":"557","author":"Salje","year":"2018","journal-title":"Nature"},{"key":"2022031117303484000_CIT0025","first-page":"1","article-title":"mice: multivariate imputation by chained equations in R","author":"van Buuren","year":"2010","journal-title":"J Stat Softw"},{"key":"2022031117303484000_CIT0026","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","article-title":"Research on dengue during World War II","volume":"1","author":"Sabin","year":"1952","journal-title":"Am J Trop Med Hyg"},{"key":"2022031117303484000_CIT0027","doi-asserted-by":"crossref","first-page":"974","DOI":"10.4269\/ajtmh.1974.23.974","article-title":"Etiologies of the experimental dengues of Siler and Simmons","volume":"23","author":"Halstead","year":"1974","journal-title":"Am J Trop Med Hyg"},{"key":"2022031117303484000_CIT0028","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/infdis\/jiw099","article-title":"Homotypic dengue virus reinfections in Nicaraguan children","volume":"214","author":"Waggoner","year":"2016","journal-title":"J Infect Dis"},{"key":"2022031117303484000_CIT0029","doi-asserted-by":"crossref","first-page":"e0004398","DOI":"10.1371\/journal.pntd.0004398","article-title":"Incomplete protection against dengue virus type 2 re-infection in Peru","volume":"10","author":"Forshey","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2022031117303484000_CIT0030","doi-asserted-by":"crossref","first-page":"12562","DOI":"10.1128\/JVI.00871-13","article-title":"High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection","volume":"87","author":"Tsai","year":"2013","journal-title":"J Virol"},{"key":"2022031117303484000_CIT0031","doi-asserted-by":"crossref","first-page":"e0005554","DOI":"10.1371\/journal.pntd.0005554","article-title":"Dissecting the human serum antibody response to secondary dengue virus infections","volume":"11","author":"Patel","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2022031117303484000_CIT0032","doi-asserted-by":"crossref","first-page":"e1002930","DOI":"10.1371\/journal.ppat.1002930","article-title":"Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope","volume":"8","author":"Austin","year":"2012","journal-title":"PLoS Pathog"},{"key":"2022031117303484000_CIT0033","doi-asserted-by":"crossref","first-page":"e1000821","DOI":"10.1371\/journal.ppat.1000821","article-title":"Natural strain variation and antibody neutralization of dengue serotype 3 viruses","volume":"6","author":"Wahala","year":"2010","journal-title":"PLoS Pathog"},{"key":"2022031117303484000_CIT0034","doi-asserted-by":"crossref","first-page":"e1486","DOI":"10.1371\/journal.pntd.0001486","article-title":"Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization","volume":"6","author":"Messer","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2022031117303484000_CIT0035","doi-asserted-by":"crossref","first-page":"108226","DOI":"10.1016\/j.celrep.2020.108226","article-title":"Antigenic variation of the dengue virus 2 genotypes impacts the neutralization activity of human antibodies in vaccinees","volume":"33","author":"Martinez","year":"2020","journal-title":"Cell Rep"},{"key":"2022031117303484000_CIT0036","doi-asserted-by":"crossref","first-page":"e01559","DOI":"10.1128\/mBio.01559-15","article-title":"Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing","volume":"6","author":"Dowd","year":"2015","journal-title":"mBio"},{"key":"2022031117303484000_CIT0037","doi-asserted-by":"crossref","first-page":"8826","DOI":"10.1128\/JVI.01314-13","article-title":"Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection","volume":"87","author":"Sukupolvi-Petty","year":"2013","journal-title":"J Virol"},{"key":"2022031117303484000_CIT0038","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.virol.2013.01.022","article-title":"The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1","volume":"439","author":"Zhou","year":"2013","journal-title":"Virology"},{"key":"2022031117303484000_CIT0039","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.aac5017","article-title":"Dengue viruses cluster antigenically but not as discrete serotypes","volume":"349","author":"Katzelnick","year":"2015","journal-title":"Science"},{"key":"2022031117303484000_CIT0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2012.03.007","article-title":"Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D\/dengue viruses","volume":"429","author":"Barban","year":"2012","journal-title":"Virology"},{"key":"2022031117303484000_CIT0041","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.AID-0022-2014","article-title":"Dengue antibody-dependent enhancement: knowns and unknowns","volume":"2","author":"Halstead","year":"2014","journal-title":"Microbiol Spectr"},{"key":"2022031117303484000_CIT0042","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imr.12367","article-title":"Fc receptors in antibody-dependent enhancement of viral infections","volume":"268","author":"Taylor","year":"2015","journal-title":"Immunol Rev"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab342\/39608541\/jiab342.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/2\/332\/42829395\/jiab342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/2\/332\/42829395\/jiab342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T17:31:07Z","timestamp":1647019867000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/2\/332\/6310132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6,26]]},"published-print":{"date-parts":[[2022,1,18]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab342","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2022,1,15]]},"published":{"date-parts":[[2021,6,26]]}}}